Epalrestat
(Synonyms: 依帕司他; ONO2235) 目录号 : GC10001
Epalrestat是一种口服有效的醛糖还原酶抑制剂，对AKR1B1和AKR1B10的IC50值分别为0.1µM和0.33µM。
Cas No.:82159-09-9
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Epalrestat is an orally active inhibitor of aldose reductases AKR1B1 and AKR1B10, with IC50 values of 0.1µM and 0.33µM, respectively[1]. Epalrestat could protect against diabetic peripheral neuropathy by relieving oxidative stress and suppressing the polyol pathway[2]. Epalrestat has been widely used as an anti-cancer agent to inhibit the proliferation of various cancer cells[3].
In vitro, Epalrestat treatment for 24 hours significantly inhibited the accumulation of galactitol in IMS32 cells exposed to galactoseemia conditions with an IC50 value of 20nM, and reduced ROS production without affecting mitochondrial function[4]. Treatment with 100μM Epalrestat for 48 hours significantly inhibited the proliferation, migration and invasion of HeLa cells[5]. Treatment of bovine aortic endothelial cells (BAECs) with 100μM Epalrestat for 24 hours increased the level of Nrf2 in the cell nucleus and stimulated the expression of thioredoxin and heme oxygenase-1[6].
In vivo, Epalrestat treatment via daily oral administration of 35mg/kg for 10 weeks can improve the metabolic disorders and renal damage in a diabetic nephropathy rat model[7]. Oral administration of 50mg/kg/day of Epalrestat for 10 consecutive days significantly inhibited tumor growth in a xenograft mouse model of MDA-MB-231 cells[8].
References:
[1] Bailly C. Moving toward a new horizon for the aldose reductase inhibitor epalrestat to treat drug-resistant cancer[J]. European Journal of Pharmacology, 2022, 931: 175191.
[2] Li Q, Wang Z, Zhou W, et al. Epalrestat protects against diabetic peripheral neuropathy by alleviating oxidative stress and inhibiting polyol pathway[J]. Neural regeneration research, 2016, 11(2): 345-351.
[3] Wang C, Yan R, Luo D, et al. Aldo-keto reductase family 1 member B10 promotes cell survival by regulating lipid synthesis and eliminating carbonyls[J]. Journal of Biological Chemistry, 2009, 284(39): 26742-26748.
[4] Yako H, Niimi N, Takaku S, et al. Epalrestat Alleviates Reactive Oxygen Species and Endoplasmic Reticulum Stress by Maintaining Glycosylation in IMS32 Schwann Cells Under Exposure to Galactosemic Conditions[J]. International Journal of Molecular Sciences, 2025, 26(4): 1529.
[5] Ji J, Xu M X, Qian T Y, et al. The AKR1B1 inhibitor epalrestat suppresses the progression of cervical cancer[J]. Molecular Biology Reports, 2020, 47(8): 6091-6103.
[6] Yama K, Sato K, Abe N, et al. Epalrestat increases glutathione, thioredoxin, and heme oxygenase-1 by stimulating Nrf2 pathway in endothelial cells[J]. Redox Biology, 2014, 4: 87.
[7] Song T, Wang R, Zhou X, et al. Metabolomics and molecular dynamics unveil the therapeutic potential of epalrestat in diabetic nephropathy[J]. International Immunopharmacology, 2024, 140: 112812.
[8] Wu X, Li X, Fu Q, et al. AKR1B1 promotes basal-like breast cancer progression by a positive feedback loop that activates the EMT program[J]. Journal of Experimental Medicine, 2017, 214(4): 1065-1079.
Epalrestat是一种口服有效的醛糖还原酶抑制剂，对AKR1B1和AKR1B10的IC50值分别为0.1µM和0.33µM[1]。Epalrestat通过缓解氧化应激及抑制多元醇通路，对糖尿病周围神经病变具有保护作用[2]。Epalrestat已作为抗癌剂广泛应用于多种癌细胞的增殖抑制研究[3]。
在体外，Epalrestat处理24小时能显著抑制半乳糖血症条件下IMS32细胞中半乳糖醇的积累，IC50值为20nM，同时降低ROS生成且不影响线粒体功能[4]。使用100µM的Epalrestat处理HeLa细胞48小时，可显著抑制细胞的增殖、迁移和侵袭能力[5]。用100µM的Epalrestat处理牛主动脉内皮细胞(BAECs)24小时，能提高细胞核内Nrf2水平，并刺激硫氧还蛋白和血红素加氧酶-1的表达[6]。
在体内，每日口服35mg/kg剂量的Epalrestat连续10周，可改善糖尿病肾病大鼠模型的代谢紊乱和肾脏损伤[7]。连续10日每日口服50mg/kg/day剂量的Epalrestat，能显著抑制MDA-MB-231细胞移植瘤小鼠的肿瘤生长[8]。
| Cell experiment [1]: | |
Cell lines | HeLa cells |
Preparation Method | The HeLa cells were cultured in Dulbecco Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin. The cells were seeded at a density of 5×103 cells per well in a 96-well plate and treated with different concentrations of Epalrestat (0, 20, 40, 60, 80, 100, and 120μM) or DMSO (as a control) in the culture medium for 48 hours. The CCK8 reagent was added, and the cells were cultured in the incubator for 1 hour, and the absorbance value was measured at a wavelength of 450nm. |
Reaction Conditions | 0, 20, 40, 60, 80, 100, and 120μM; 48h |
Applications | Epalrestat treatment significantly inhibited the viability of HeLa cells in a dose-dependent manner. |
| Animal experiment [2]: | |
Animal models | Male Sprague-Dawley rats |
Preparation Method | Eight-week-old male Sprague-Dawley rats were all housed in a barrier system. The temperature was maintained at 21±2°C, the humidity at 50±5%, and the light/dark cycle was 12 hours per day. The animals had free access to food and water. All rats were randomly divided into three groups: the healthy control group, the diabetic nephropathy (DN) group, and the Epalrestat group. After the DN group and the Epalrestat group rats were fed a high-fat diet (HFD) for 8 weeks, rats were intraperitoneally injected with streptozotocin (35mg/kg, dissolved in pH 4.5 citrate buffer) while the healthy control group rats were intraperitoneally injected with citrate buffer. Rats with blood glucose levels higher than 16.7mM were identified as diabetic rats. The rats in the Epalrestat group were orally administered Epalrestat (35mg/kg) daily for 10 weeks. The renal function-related parameters of each group were tested. |
Dosage form | 35mg/kg/day for 10 weeks; p.o. |
Applications | Epalrestat treatment regulated the dyslipidemia of DN rats and reduced the levels of serum creatinine, blood urea nitrogen, and urinary albumin excretion rate. |
References: | |
| Cas No. | 82159-09-9 | SDF | |
| 别名 | 依帕司他; ONO2235 | ||
| 化学名 | 2-[(5Z)-5-[(E)-2-methyl-3-phenylprop-2-enylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]acetic acid | ||
| Canonical SMILES | CC(=CC1=CC=CC=C1)C=C2C(=O)N(C(=S)S2)CC(=O)O | ||
| 分子式 | C15H13NO3S2 | 分子量 | 319.4 |
| 溶解度 | ≥ 6.375mg/mL in DMSO with gentle warming | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.1309 mL | 15.6544 mL | 31.3087 mL |
| 5 mM | 626.2 μL | 3.1309 mL | 6.2617 mL |
| 10 mM | 313.1 μL | 1.5654 mL | 3.1309 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet